Advances in the development of new biologics in inflammatory bowel disease

44Citations
Citations of this article
107Readers
Mendeley users who have this article in their library.

Abstract

Biologics have revolutionized the therapeutic approach in inflammatory bowel disease (IBD). Anti-tumor necrosis factor (anti-TNF) agents infliximab and adalimumab currently constitute the major biological therapy in IBD. Additional anti-TNFs such as golimumab and other new biologics are currently being developed for both anti-TNF-naïve and -resistant patients. These include anti-integrins (vedolizumab and etrolizumab), a JAK inhibitor (tofacitinib) and an anti-anti-interleukin (IL)-23 and IL-12 antibody (ustekinumab), among additional drugs in development. The following review discusses the indications, efficacy and safety issues for these novel medications.

Cite

CITATION STYLE

APA

Ungar, B., & Kopylov, U. (2016). Advances in the development of new biologics in inflammatory bowel disease. Annals of Gastroenterology. Hellenic Society of Gastroenterology. https://doi.org/10.20524/aog.2016.0027

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free